Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

（文章来源：证券日报） 证券日报网讯 9月1日晚间，诺思兰德发布公告称，公司第六届监事会第十六次会议审议通过了《关于 取消监事会并修订〈公司章程〉的议案》等。 ...

Core Viewpoint - The company announced the approval of multiple resolutions, including the cancellation of the supervisory board and amendments to the company's articles of association during the 22nd meeting of the sixth board of directors [2] Group 1 - The company held its 22nd meeting of the sixth board of directors on September 1 [2] - The resolutions passed include the proposal to cancel the supervisory board [2] - Amendments to the company's articles of association were also approved [2]

Group 1 - The company, Norland, announced that it will hold its second extraordinary general meeting of shareholders on September 17, 2025 [1] - The agenda for the meeting includes the proposal to cancel the supervisory board and amend the company's articles of association [1]

Meeting and Attendance - The board meeting was convened and conducted in accordance with the Company Law and the Articles of Association, with valid voting results [1] - All 9 directors were present or authorized to attend, with some participating via communication means due to work commitments [1] Agenda Review - The proposal to abolish the supervisory board and amend the Articles of Association was approved, transferring the supervisory board's powers to the audit committee of the board [1] - The original rules governing the supervisory board were simultaneously abolished, and amendments to the Articles of Association were proposed for shareholder authorization [1] Internal Management System - A proposal to establish and amend certain internal management systems was approved, aimed at enhancing corporate governance and promoting standardized operations [2][4] - This proposal includes several sub-proposals related to various management systems, such as the rules for board meetings, shareholder meetings, and related party transaction management [2][4] Shareholder Meeting - The board proposed to convene the second extraordinary general meeting of shareholders in 2025 on September 17 to review related proposals [6] - This proposal does not involve related party transactions and does not require avoidance of voting [6]

Group 1 - The company has decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and will amend the relevant provisions in the Articles of Association accordingly [1][2] - The proposal to abolish the supervisory board and amend the Articles of Association has been approved by the supervisory board and will be submitted for shareholder meeting approval [2] - The proposal to abolish the "Rules of Procedure for the Supervisory Board of Beijing Northland Biotechnology Co., Ltd." has also been approved, as the supervisory board will no longer exist [2] Group 2 - The meeting was convened in accordance with the Company Law and the Articles of Association, with all voting results being legal and valid [1] - All three supervisors were present or authorized to attend the meeting, with one supervisor participating via telecommunication due to work commitments [1] - The proposals do not involve related party transactions and do not require abstention from voting [2]

证券代码：430047 证券简称：诺思兰德 公告编号：2025-066 北京诺思兰德生物技术股份有限公司独立董事工作制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.07： 《修订〈独立董事工作制 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为进一步完善北京诺思兰德生物技术股份有限公司（以下简称"公 司"）治理结构，充分发挥公司独立董事作用，促进公司规范运作，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《北京证券交易所上市公司持续监管办法（试行）》《上市公 司独立董事管理办法》、 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-064 北京诺思兰德生物技术股份有限公司利润分配管理制度 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.05： 《修订〈利润分配管理制 第一章 总则 第一条 为进一步规范北京诺思兰德生物技术股份有限公司（以下简称"公 司"）的利润分配行为，建立科学、持续、稳定的分配机制，增强利润分配的透 明度，保证公司长远可持续发展，保护中小投资者合法权益，根据《中华人民共 和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》、 《北京证券交 易所股票上市规则》、 ...

Group 1 - The core point of the article is the establishment and operational framework of Beijing Northland Biotechnology Co., Ltd., including its legal foundation, organizational structure, and governance principles [1][2][3][4]. - The company was established as a joint-stock company based on the transformation of Beijing Northland Biotechnology Co., Ltd. and is registered in Haidian District, Beijing [2][3]. - The registered capital of the company is RMB 274.271974 million [3]. Group 2 - The company's business purpose is to operate legally, combining production and capital operations, focusing on the development of new drug projects, and expanding related industries to achieve multi-faceted development [5]. - The company’s business scope includes technology development, transfer, and consulting, investment and asset management, sales of biological products, and various forms of drug retail and wholesale [5]. Group 3 - The company has issued a total of 274,271,974 shares, all of which are RMB ordinary shares [6][7]. - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [7][8]. - The company is prohibited from repurchasing its own shares except under specific circumstances, such as reducing registered capital or merging with another company [8][9]. Group 4 - The company’s shares must be transferred in accordance with the law, and the company does not accept its shares as collateral [9][10]. - Major shareholders and executives are restricted from selling their shares within two full accounting years if the company has not yet made a profit [10][11]. Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [11][12]. - The company must hold annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [12][13][14].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-061 北京诺思兰德生物技术股份有限公司股东会议事规则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.02： 《修订〈股东会议事规则〉》， 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总 则 则。 第一条 为规范北京诺思兰德生物技术股份有限公司（以下简称"公司"）行 为，保证股东会依法行使职权，根据《中华人民共和国公司法》 （以下简称"《公 司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股东会 规则》、 《北京证券交易所股票上市规则》 （以下简称"《股票上市规则》"）、 《 ...